Two New Generic Alternatives to Osteoarthritis Drug Approved
Alternatives to Mobic receive FDA approval.
The FDA recently approved two new generic versions of Boehringer Ingelheim Pharmaceuticals Inc.'s popular anti-arthritis medication, Mobic. This medication, which treats the symptoms of both osteo- and rheumatoid arthritis, had sales of over a billion dollars in the United States during the last fiscal year. The two generic alternatives, known by the generic name Meloxicam, are produced by the Israeli company Teva Pharmaceutical Industries Ltd and Par Pharmaceuticals Co, Inc, and are available in doses of 7.5 and 15 mg. Find out more about Meloxicam here.